Nephropathy - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 71 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Nephropathy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Nephropathy - Pipeline Review, H2 2014', provides an overview of the Nephropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nephropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nephropathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Nephropathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Nephropathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Nephropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nephropathy Overview 7
Therapeutics Development 8
Pipeline Products for Nephropathy - Overview 8
Pipeline Products for Nephropathy - Comparative Analysis 9
Nephropathy - Therapeutics under Development by Companies 10
Nephropathy - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Nephropathy - Products under Development by Companies 15
Nephropathy - Companies Involved in Therapeutics Development 16
Alnylam Pharmaceuticals, Inc. 16
Anthera Pharmaceuticals� Inc. 17
Boehringer Ingelheim GmbH 18
IGAN Biosciences 19
Inotek Pharmaceuticals Corporation 20
Ischemix 21
Promedior, Inc. 22
Rigel Pharmaceuticals, Inc. 23
Nephropathy - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Adipose Stem Cell Therapy for IgA Nephropathy - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ALN-CC5 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
blisibimod - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CMX-2043 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
fostamatinib disodium - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
IgA Proteases for Nephropathy - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
imatinib mesylate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
INO-4885 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PRM-151 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
R-801 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
R-901 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecule to Inhibit Casein Kinase 2 for Cancer and Nephritis - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Nephropathy - Recent Pipeline Updates 54
Nephropathy - Dormant Projects 66
Nephropathy - Discontinued Products 67
Nephropathy - Product Development Milestones 68
Featured News & Press Releases 68
Oct 01, 2014: Anthera Pharmaceuticals Announces Update On Strategic Partnership Discussions For Blisibimod 68
Sep 25, 2013: Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting 68
Jun 24, 2013: Anthera Pharma Initiates BRIGHT-SC Phase II Clinical Study In IgA Nephropathy With Blisibimod 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 71
Disclaimer 71

List of Tables
Number of Products under Development for Nephropathy, H2 2014 8
Number of Products under Development for Nephropathy - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Nephropathy - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 16
Nephropathy - Pipeline by Anthera Pharmaceuticals� Inc., H2 2014 17
Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H2 2014 18
Nephropathy - Pipeline by IGAN Biosciences, H2 2014 19
Nephropathy - Pipeline by Inotek Pharmaceuticals Corporation, H2 2014 20
Nephropathy - Pipeline by Ischemix, H2 2014 21
Nephropathy - Pipeline by Promedior, Inc., H2 2014 22
Nephropathy - Pipeline by Rigel Pharmaceuticals, Inc., H2 2014 23
Assessment by Monotherapy Products, H2 2014 24
Number of Products by Stage and Target, H2 2014 26
Number of Products by Stage and Mechanism of Action, H2 2014 28
Number of Products by Stage and Route of Administration, H2 2014 30
Number of Products by Stage and Molecule Type, H2 2014 32
Nephropathy Therapeutics - Recent Pipeline Updates, H2 2014 54
Nephropathy - Dormant Projects, H2 2014 66
Nephropathy - Discontinued Products, H2 2014 67